Add
ACAD to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| ACAD > SEC Filings for ACAD > Form 8-K on 13-Jul-2012 | All Recent SEC Filings |
13-Jul-2012
Other Events
ACADIA Pharmaceuticals Inc. is scheduled to present at the 7th Annual JMP Securities Healthcare Conference on Friday, July 13, 2012, at 11:00 a.m. Eastern Time. During the presentation, ACADIA will provide an update on its pipeline, including the status of its ongoing Phase III efficacy, tolerability and safety trial with pimavanserin for Parkinson's disease psychosis (the "-020 Study"). ACADIA is approaching completion of enrollment in the -020 Study with 90 percent of the planned patient enrollment completed. ACADIA expects to complete enrollment in this trial during August 2012.
ACADIA also is reporting that AM-831, a compound under development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd., did not meet pre-determined criteria for further development in Phase I testing and, as a result, the parties jointly have decided to discontinue the development of AM-831.
Forward-Looking Statements
Certain statements in this report that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the timing of completion of trial enrollment. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those stated in any such statements due to various factors, including uncertainties about clinical trials, some of which are discussed in ACADIA's annual report on Form 10-K for the year ended December 31, 2011 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof.
|
|